Anti-PCSK9 Neutralizing Antibody | 71207

Anti-PCSK9 Neutralizing Antibody | 71207 | Gentaur US, UK & Europe Disrtribition

Category: Cholesterol-Related/Antibody

Application: Useful as an inhibitor of PCSK9-LDLR binding using the PCSK9[Biotinylated]-LDLR Binding Assay Kit, Cat. #72002.

Background: PCSK9 is a crucial player in the regulation of plasma cholesterol homeostasis. It binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.

Description: Neutralizing recombinant human antibody (IgG1) recognizing the LDLR binding region of human PCSK9.

Product Type: Antibody

Shippement Condition: -80°C